CN102282148A - 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 - Google Patents
11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 Download PDFInfo
- Publication number
- CN102282148A CN102282148A CN2009801503255A CN200980150325A CN102282148A CN 102282148 A CN102282148 A CN 102282148A CN 2009801503255 A CN2009801503255 A CN 2009801503255A CN 200980150325 A CN200980150325 A CN 200980150325A CN 102282148 A CN102282148 A CN 102282148A
- Authority
- CN
- China
- Prior art keywords
- salt
- batch
- ray diffraction
- sample
- hcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/22—Tricarboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D201/00—Preparation, separation, purification or stabilisation of unsubstituted lactams
- C07D201/02—Preparation of lactams
- C07D201/10—Preparation of lactams from cycloaliphatic compounds by simultaneous nitrosylation and rearrangement
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
峰位置(2-θ°,±0.5°) | 相对强度 |
7.1 | 弱 |
7.8 | 中 |
10.2 | 强 |
10.9 | 弱 |
14.2 | 中 |
15.7 | 中 |
16.8 | 中 |
17.1 | 弱 |
17.6 | 弱 |
18.5 | 弱 |
18.7 | 弱 |
20.7 | 弱 |
21.4 | 中 |
22.4 | 强 |
23.3 | 弱 |
24.2 | 弱 |
25.1 | 弱 |
25.8 | 弱 |
26.2 | 弱 |
26.9 | 弱 |
27.5 | 弱 |
28.7 | 弱 |
29.3 | 弱 |
31.0 | 弱 |
32.4 | 弱 |
37.3 | 弱 |
38.6 | 弱 |
39.9 | 弱 |
41.6 | 弱 |
Claims (17)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12166808P | 2008-12-11 | 2008-12-11 | |
US61/121,668 | 2008-12-11 | ||
PCT/SG2009/000473 WO2010068181A1 (en) | 2008-12-11 | 2009-12-09 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6)1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27)j16,21,23-decaene citrate salt |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102282148A true CN102282148A (zh) | 2011-12-14 |
CN102282148B CN102282148B (zh) | 2014-12-24 |
Family
ID=41666397
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980150325.5A Active CN102282148B (zh) | 2008-12-11 | 2009-12-09 | 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 |
Country Status (24)
Country | Link |
---|---|
US (2) | US8980873B2 (zh) |
EP (1) | EP2376499B1 (zh) |
JP (1) | JP5669748B2 (zh) |
KR (1) | KR101729918B1 (zh) |
CN (1) | CN102282148B (zh) |
AR (2) | AR074724A1 (zh) |
AU (1) | AU2009325147B2 (zh) |
BR (1) | BRPI0922736B1 (zh) |
CA (1) | CA2746058C (zh) |
DK (1) | DK2376499T3 (zh) |
ES (1) | ES2536558T3 (zh) |
HK (1) | HK1161877A1 (zh) |
HR (1) | HRP20150428T1 (zh) |
IL (3) | IL213418A0 (zh) |
MX (1) | MX2011006206A (zh) |
MY (1) | MY160005A (zh) |
NZ (1) | NZ593223A (zh) |
PL (1) | PL2376499T3 (zh) |
PT (1) | PT2376499E (zh) |
RU (1) | RU2527970C2 (zh) |
SG (1) | SG171907A1 (zh) |
TW (1) | TWI449705B (zh) |
WO (1) | WO2010068181A1 (zh) |
ZA (1) | ZA201104032B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013163917A1 (zh) | 2012-04-13 | 2013-11-07 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
CN105061467A (zh) * | 2015-08-28 | 2015-11-18 | 苏州立新制药有限公司 | 一种帕克替尼的制备方法 |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2527970C2 (ru) | 2008-12-11 | 2014-09-10 | Селл Терапьютикс,Инк. | Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена |
DK2376500T3 (en) * | 2008-12-11 | 2015-05-04 | Cti Biopharma Corp | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007058627A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Oxygen linked pyrimidine derivatives |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5728536A (en) | 1993-07-29 | 1998-03-17 | St. Jude Children's Research Hospital | Jak kinases and regulation of Cytokine signal transduction |
US6136595A (en) | 1993-07-29 | 2000-10-24 | St. Jude Children's Research Hospital | Jak kinases and regulations of cytokine signal transduction |
PL366774A1 (en) * | 2001-05-14 | 2005-02-07 | Pfizer Products Inc. | The citrate salt of 5,8,14-triazatetracyclo(10.3.1.02,11.04,9)-hexadeca-2.(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
US6433018B1 (en) | 2001-08-31 | 2002-08-13 | The Research Foundation Of State University Of New York | Method for reducing hypertrophy and ischemia |
CA2468705A1 (en) * | 2001-11-29 | 2003-06-05 | Pfizer Products Inc. | Succinic acid salts of 5,8,14-triazatetracyclo'10.3.1.0<2,11>.0<4,9>-hexadeca-2(11),3,5,7,9-pentaene and pharmaceutical compositions thereof |
RU2527970C2 (ru) | 2008-12-11 | 2014-09-10 | Селл Терапьютикс,Инк. | Цитрат 11-(2-пирролидин-1-ил-этокси)-14,19-диокса-5,7,26-триазатетрацикло[19.3.1.1(2,6).1(8,12)]гептакоза-1(25),2(26),3,5,8,10,12(27),16,21,23-декаена |
-
2009
- 2009-12-09 RU RU2011126173/04A patent/RU2527970C2/ru active
- 2009-12-09 BR BRPI0922736-9A patent/BRPI0922736B1/pt active IP Right Grant
- 2009-12-09 DK DK09788621T patent/DK2376499T3/en active
- 2009-12-09 EP EP09788621.2A patent/EP2376499B1/en active Active
- 2009-12-09 ES ES09788621.2T patent/ES2536558T3/es active Active
- 2009-12-09 PT PT97886212T patent/PT2376499E/pt unknown
- 2009-12-09 US US13/133,297 patent/US8980873B2/en active Active
- 2009-12-09 AU AU2009325147A patent/AU2009325147B2/en active Active
- 2009-12-09 MX MX2011006206A patent/MX2011006206A/es active IP Right Grant
- 2009-12-09 CA CA2746058A patent/CA2746058C/en active Active
- 2009-12-09 SG SG2011040060A patent/SG171907A1/en unknown
- 2009-12-09 KR KR1020117015738A patent/KR101729918B1/ko active IP Right Grant
- 2009-12-09 PL PL09788621T patent/PL2376499T3/pl unknown
- 2009-12-09 WO PCT/SG2009/000473 patent/WO2010068181A1/en active Application Filing
- 2009-12-09 MY MYPI2011002647A patent/MY160005A/en unknown
- 2009-12-09 JP JP2011540664A patent/JP5669748B2/ja active Active
- 2009-12-09 CN CN200980150325.5A patent/CN102282148B/zh active Active
- 2009-12-09 NZ NZ593223A patent/NZ593223A/xx unknown
- 2009-12-11 TW TW098142605A patent/TWI449705B/zh active
- 2009-12-11 AR ARP090104834A patent/AR074724A1/es not_active Application Discontinuation
-
2011
- 2011-05-31 ZA ZA2011/04032A patent/ZA201104032B/en unknown
- 2011-06-06 IL IL213418A patent/IL213418A0/en unknown
-
2012
- 2012-03-08 HK HK12102375.7A patent/HK1161877A1/zh unknown
-
2015
- 2015-02-13 US US14/621,726 patent/US9624242B2/en active Active
- 2015-04-20 HR HRP20150428TT patent/HRP20150428T1/hr unknown
-
2017
- 2017-01-26 IL IL250310A patent/IL250310A0/en unknown
-
2019
- 2019-03-20 AR ARP190100701A patent/AR114133A2/es unknown
-
2021
- 2021-12-26 IL IL289379A patent/IL289379A/en unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007058627A1 (en) * | 2005-11-16 | 2007-05-24 | S*Bio Pte Ltd | Oxygen linked pyrimidine derivatives |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013163917A1 (zh) | 2012-04-13 | 2013-11-07 | 连云港金康和信药业有限公司 | 化合物jk12a及其制备 |
CN105061467A (zh) * | 2015-08-28 | 2015-11-18 | 苏州立新制药有限公司 | 一种帕克替尼的制备方法 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102282148A (zh) | 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 | |
NO342150B1 (no) | Krystallinsk form A av [4-(3-fluor-5-trifluormetylpyridin-2-yl)-piperazin-1-yl]-[5-metansulfonyl-2-((S)-2,2,2-trifluor-1-metyl-etoksy)-fenyl]-metanon, metode for fremstilling av denne, farmasøytisk preparat omfattende denne samt anvendelse av denne for behandling av sykdom | |
AU2017283651A1 (en) | Solid state forms of spiro-oxindole compounds | |
DK2376500T3 (en) | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaenmaleatsalt | |
WO2015085972A1 (en) | NOVEL SALTS OF 3-(2-IMIDAZO[1,2-b]PYRIDAZIN-3-YLETHYNYL)-4-METHYL-N-[4-[(4-METHYL- 1-PIPERAZINYL)METHYL]-3-(TRIFLUOROMETHYL)PHENYL] BENZAMIDE | |
CN102762577B (zh) | 9e-15-(2-吡咯烷-1-基-乙氧基)-7,12,25-三氧杂-19,21,24-三氮杂-四环[18.3.1.1(2,5).1(14,18)]二十六碳-1(24),2,4,9,14,16,18(26),20,22-壬烯柠檬酸盐 | |
US20160060220A1 (en) | Process for preparation of 2-chloro-n-(4-chloro-3-pyridin-2-ylphenyl)-4-methylsulfonylbenzamide solid forms | |
CA3130247C (en) | Fgfr inhibitor compound in solid form and preparation method therefor | |
US10301344B2 (en) | L-proline complex of sodium-glucose cotransporter 2 inhibitor, monohydrate and crystal form thereof | |
WO2017032349A1 (en) | Salts of 5-fluoro-3-phenyl-2-[(1s)-1-(9h-purin-6-ylamino)propyl]quinazolin-4-one and preparation thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: CELL THERAPEUTICS EUROP S. R. L. (US) Free format text: FORMER OWNER: S* Effective date: 20130319 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20130319 Address after: Washington State Applicant after: Cell Therapeutics Europ S. R. L. (US) Address before: Singapore Singapore Applicant before: S. Bio Pte Ltd. |
|
C53 | Correction of patent of invention or patent application | ||
CB02 | Change of applicant information |
Address after: Washington State Applicant after: CTI BIOLOGICAL MEDICAL INC. Address before: Washington State Applicant before: Cell Therapeutics Europ S. R. L. (US) |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: CELL THERAPEUTICS EUROP S. R. L. (US) TO: CTI BIOLOGICAL PHARMACEUTICAL CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |